Synergistic bacterial compositions and methods of production and use thereof
Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
1. A method of treating or preventing an occurrence or a recurrence of a Clostridium difficile infection, comprising administering to a human subject in need thereof an effective amount of a therapeutic composition comprising a first purified bacterial population consisting of bacteria comprising 16S rDNA sequence at least about 97% identical to a 16S rDNA sequence present in a reference Collinsella aerofaciens OTU, and a second purified bacterial population consisting of bacteria comprising 16S rDNA sequence at least about 97% identical to a 16S rDNA sequence present in a reference bacterium of the family Clostridiaceae listed in Table 1, wherein a synergistic combination of the first purified bacterial population and the second purified bacterial population is cytotoxic or cytostatic to a pathogenic bacterium, wherein the therapeutic composition is administered under conditions such that the first purified bacterial population and the second purified bacterial population exert an inhibitory effect on a pathogenic bacterium present in or entering into the gastrointestinal tract of the human subject, such that the number of Clostridium difficile bacteria present in the gastrointestinal tract is not detectably increased or is detectably decreased over a period of time.
2. The method of claim 1 , wherein the number of Clostridium difficile bacteria present in or excreted from the gastrointestinal tract of the human subject is detectably reduced within one month of administration of the bacterial composition.
3. The method of claim 1 , wherein the first purified bacterial population and the second purified bacterial population synergistically interact to be cytotoxic and/or cytostatic to the Clostridium difficile bacteria as demonstrated by a CivSim assay.
4. The method of claim 1 , wherein the therapeutic composition is orally administered.
5. The method of claim 1 , wherein the therapeutic composition comprises a medical food.
6. The method of claim 1 , wherein the composition is capable of inhibiting proliferation of the pathogenic bacterium when the bacterial population of the composition is present at a concentration at least equal to the concentration of the pathogenic bacterium.
7. The method of claim 1 , wherein the first purified bacterial population and the second purified bacterial population are capable of functionally populating the gastrointestinal tract of a human subject to whom the composition is administered.
8. The method of claim 7 , wherein the functional populating of the gastrointestinal tract comprises preventing, treating, reducing the severity of or reducing a symptom of a dysbiosis of the gastrointestinal tract.
9. The method of claim 7 , wherein the functional populating of the gastrointestinal tract comprises i) reducing the number of one or more types of pathogenic bacteria in the gastrointestinal tract; or ii) increasing the number of one or more non-athogenic bacteria in the gastrointestinal tract.